Skip to content

Quell-FM Transcutaneous Electrical Nerve Stimulator

by Neurometrix, Inc.

De Novo DEN210046

Active United States

De Novo

Valid until

No expiry

De Novo grant is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Source FDA De Novo, synced 6 Oct 2026.

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA De NovoDENG De Novo granted · Direct NumberDEN210046 Date18 May 2022DecidedStatusActive

Official records

From the FDA record

Received by the FDA
5 Oct 2021
FDA decision
18 May 2022
FDA review time
225 days from receipt to decision

From the FDA De Novo record DEN210046 (openFDA), as read on 6 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA De Novo Active

Specification

De Novo

Full name
Quell-FM
De Novo Number
FDA product code
QSQ
Device class
Class II
Regulation
21 CFR Part 882.5888
Advisory committee
Neurology
FDA decision
DENG De Novo granted

Overview

AI-generated summary, 20 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Quell-FM is a transcutaneous electrical nerve stimulation (TENS) device classified as a Class 2 Neurology device (product code QSQ). It is designed to provide electrical stimulation to help reduce fibromyalgia symptoms in adults with high pain sensitivity, leveraging transcutaneous nerve modulation to alleviate discomfort. The device operates on the principle of delivering low-level electrical impulses through the skin to modulate pain perception. Its regulatory designation aligns with the FDA’s classification for neuromodulation devices intended for chronic pain management.

The Quell-FM is intended for use during sleep and is supplied with compatible NeuroMetrix electrodes. It is cleared under FDA 510(k) (DEN210046) via the Direct pathway, adhering to regulatory standards for Class 2 devices. No explicit sterility or single-use/reusable designation is provided, though its intended use suggests a reusable design with proper electrode maintenance. The device is not labeled for MRI compatibility or other imaging environments. Storage and handling follow standard electrical medical device protocols as outlined in its user manual.

Devices cleared under DEN210046

11 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under DEN210046
UDI-DISize and differences
Quell 1.0 QE-BK-AGN
NEUROMETRIX, INC.
QE-BK-AGN00851221006766
Prescription: yes; Single use: yes
On the market
Quell 2.0 QE-NBK-LBL
NEUROMETRIX, INC.
QE-NBK-LBL00851221006742
Prescription: yes; Single use: yes
On the market
Quell 2.0 QE-NBK-SBL
NEUROMETRIX, INC.
QE-NBK-SBL00851221006735
Prescription: yes; Single use: yes
On the market
Quell Charger Adapter QE-CH1
NEUROMETRIX, INC.
QE-CH100851221006797
Prescription: no; Single use: yes
On the market
Quell Charger Cable QE-CH2
NEUROMETRIX, INC.
QE-CH200851221006780
Prescription: no; Single use: yes
On the market
QUELL FIBROMYALGIA QE-FMG
NEUROMETRIX, INC.
QE-FMG00851221006643
Prescription: yes; Single use: no
On the market
QUELL FIBROMYALGIA QE-FMG-4
NEUROMETRIX, INC.
QE-FMG-400851221006384
Prescription: yes; Single use: no
On the market
Quell Fibromyalgia QE-FMG-RPL
NEUROMETRIX, INC.
QE-FMG-RPL00851221006810
Prescription: yes; Single use: yes
On the market
QUELL FIBROMYALGIA QE-FMP
NEUROMETRIX, INC.
QE-FMP00851221006650
Prescription: yes; Single use: no
On the market
Quell Fibromyalgia QE-NBK-RBL
NEUROMETRIX, INC.
QE-NBK-RBL00851221006513
Prescription: yes; Single use: no
On the market
Quell QE-STX
NEUROMETRIX, INC.
QE-STX00851221006704
Prescription: yes; Single use: yes
On the market

Other devices from Neurometrix, Inc.

See all devices from Neurometrix, Inc. →